Key facts
- Elucid Bioimaging’s last known valuation is $288.0M (Oct 2025).
- It has raised $163.2M across 3 recorded rounds; the latest was Early Stage VC ($36.5M) in Oct 2025.
- Notable investors include Sand Hill Angels, IAG Capital Partners, University of Michigan Endowment, Elevage Medical Technologies, Angel Physicians Fund — 24 tracked in total.
- Elucid Bioimaging has filed 2 Form Ds with the SEC since 2013, most recently Nov 2023 ($79.0M sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Elucid Bioimaging
Funding rounds
3 roundsAbout Elucid Bioimaging
Developer of an imaging system designed to improve patient outcomes at a reduced cost by applying artificial intelligence to vascular diagnostic imaging. The company's system objectively quantifies the extent and stability of arterial plaque and offers an economically efficient and non-invasive method for capturing patient health information, enabling cardiovascular pathologists to enhance their patient care and provide comprehensive and accurate clinical insights.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Employees
- 127
- Website
- elucid.com/
- Ownership
- Privately Held (backing)
Elucid Bioimaging doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elucid Bioimaging shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elucid Bioimaging in its N-PORT filings yet. We sweep new filings monthly.